Make us your home page

Today’s top headlines delivered to you daily.

(View our Privacy Policy)

Drugmakers in a race to develop new anti-cholesterol medicines

NEW YORK — A handful of drugmakers are racing to develop a new class of medicines that they believe could be the biggest weapon against heart disease since statins were introduced in the 1980s.

The contest is taking place largely out of public view, but researchers and industry analysts say excitement is building over the injectable medicines. They work by blocking PCSK9, a protein whose natural function is to preserve levels of "bad" LDL cholesterol in the bloodstream.

Researchers in Paris, Montreal and Dallas, through experiments with thousands of patients that began in 1999, discovered the gene behind PCSK9 and deciphered its function.

Biotechnology company Regeneron and its big pharmaceutical partner Sanofi are now ahead of the pack in developing a drug that goes after PCSK9. A single injection of their medicine, called REGN727, slashed LDL levels by more than 60 percent for a month in an early trial. Results from mid-stage studies are expected later this year.

"The PCSK9 mechanism is perhaps one of the best examples we have in all of medicine of how the study of genetics can identify new targets for developing new therapies," said Dr. Daniel Rader, a noted heart researcher at the University of Pennsylvania.

Although no serious side effects have been seen with REGN727, larger trials are needed to rule out problems such as liver toxicity or raised blood pressure that have wrecked other promising heart drugs, including Pfizer Inc.'s experimental torcetrapib.

Rader, who is a consultant to several of the companies developing PCSK9 inhibitors, said most drugmakers are working on once-a-month injections that would likely be self-administered by patients using very small needles. Some drugs might eventually be administered every two to three months, he said.

Amgen Inc., Merck & Co., Alnylam Pharmaceuticals Inc. and a partnership between Bristol-Myers Squibb Co. and Isis Pharmaceuticals Inc. are in hot pursuit with rival drugs of their own.

The anti-PCSK9 medicines are expected to be used alongside statins, such as Pfizer's Lipitor and AstraZeneca's Crestor, for patients who do not achieve cholesterol-lowering goals with statins alone.

They would also be used on their own for a much smaller group who cannot tolerate statins — oral drugs with global annual sales of $20 billion that inhibit the liver's production of LDL cholesterol.

In the United States, more than 10 million patients could ultimately be candidates for the new family of medicines. Industry analysts say the products could command $1,000 a month or more because of their potential importance to high-risk patients. Statins cost about $130 a month for branded pills like Lipitor.

Drugmakers in a race to develop new anti-cholesterol medicines 08/27/11 [Last modified: Friday, August 26, 2011 8:28pm]
Photo reprints | Article reprints


Join the discussion: Click to view comments, add yours

  1. Half of Florida lawmakers fail or nearly fail review of support for public records

    State Roundup

    WEST PALM BEACH — Half of Florida's legislators failed or nearly failed in a review of their support for public records and meetings given by Florida newspapers and an open-government group after this year's legislative sessions.

    State Senator Bill Galvano, R- Bradenton (left) and Florida House Speaker Richard Corcoran ranked on opposite sides of the spectrum in an analysis of support for open records. Galvano scored a B-minus and Corcoran scored a D-plus.
[Times file photo]
  2. Yale dean on leave over offensive Yelp reviews leaves post

    Bizarre News

    NEW HAVEN, Conn. — A Yale University dean who was placed on leave over offensive reviews she posted on Yelp has left her position at the Ivy League institution, school officials said Tuesday.

  3. Federal agencies demand records from SeaWorld theme park


    ORLANDO — Two federal agencies are reportedly demanding financial records from SeaWorld.

    Killer whales Ikaika and Corky participate in behaviors commonly done in the wild during SeaWorld's Killer Whale educational presentation in this photo from Jan. 9. SeaWorld has been subpoenaed by two federal agencies for comments that executives and the company made in August 2014 about the impact from the "Blackfish" documentary. 
[Nelvin C. Cepeda/San Diego Union-Tribune/TNS]
  4. The people you meet along O.J. Howard Lane


    OJ Howard (far right) is seen in a photo from his adolescent years at Bethesda Missionary Baptist Church in Prattville, Ala., on Wednesday, May 3, 2017. Howard served as an usher in addition to attending regular services at this church.